Evidence map›Paper›PMID 39052108›Full record

ArticleJournal of cancer research and clinical oncology2024

IKZF3 amplification predicts worse prognosis especially in intestinal-type gastric cancer.

Zhaomeng Cui, Huaiyu Liang, Rongkui Luo, Wen Huang, Wei Yuan, Lei Zhang, Lijuan Luan, Jieakesu Su, Jie Huang, Chen Xu and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of cancer research and clinical oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. [IKZF3/Aiolos and tumors].Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2025
    Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Zhaomeng Cui *Department of Pathology, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.
Huaiyu Liang *Department of Pathology, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.
Rongkui LuoDepartment of Pathology, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.
Wen HuangDepartment of Pathology, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.
Wei YuanDepartment of Pathology, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.
Lei ZhangDepartment of Pathology, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.
Lijuan LuanDepartment of Pathology, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.
Jieakesu SuDepartment of Pathology, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.
Jie HuangDepartment of Pathology, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.
Chen XuDepartment of Pathology, Zhongshan Hospital, Fudan University, Shanghai, 200032, China. xu.chen@zs-hospital.sh.cn.
Yingyong HouDepartment of Pathology, Zhongshan Hospital, Fudan University, Shanghai, 200032, China. hou.yingyong@zs-hospital.sh.cn.ORCID https://orcid.org/0000-0001-9156-2305

Funding

National Key Clinical Specialty Discipline Construction Program of China YWP2023-001National Key Research and Development Program of China 2021YFF1201001
6 · The paper itself

Abstract

purposeIKAROS family zinc finger 3 (IKZF3) is an oncogene involved in different malignancies, particularly in the development and malignant progression of lymphocytes. However, IKZF3 amplification and clinical significance in gastric cancers (GCs) remain unexplored.

methodsWe examined IKZF3 amplification status in 404 GCs with HER2 amplification status using tissue microarray (TMA) and fluorescence in situ hybridization (FISH) assays.

resultsIKZF3 amplification was detected in 6.9% (28/404) of all GC patients, with higher rates in intestinal-type gastric cancer (IGC) (11.22%, 22/196) compared to other types (2.88%, 6/208). HER2 amplification was identified in 16.09% (65/404) of all GC patients, with higher rates in IGC (20.92%, 41/196) compared to other types (11.54%, 24/208). Co-amplification of IKZF3 and HER2 was detected in 8.16% (16/196) of IGC patients and in 2.40% (5/208) of other types. IKZF3 amplification showed significant correlation with IGC (P = 0.001) and HER2 amplification (P = 0.0001). IKZF3 amplification exhibited significantly worse disease-free survival (DFS) (P = 0.014) and overall survival (OS) (P = 0.018) in GC patients, particularly in IGC (DFS: P < 0.001; OS: P < 0.001), rather than other types. Cox regression analysis demonstrate IKZF3 amplification as an independent poor prognostic factor in all GCs (P = 0.006, P = 0.004 respectively) and in IGC patients, regardless of stages I-II or III-IV (P = 0.007, P = 0.004 respectively). On the other hand, HER2 amplification was significantly associated with worse DFS (P = 0.008) and OS (P = 0.01) in IGC patients, but not in all GCs and in multivariate analysis. Within the subset of patients with HER2 amplification, those also exhibiting IKZF3 amplification displayed potential poorer prognosis (P = 0.08, P = 0.11 respectively).

conclusionIKZF3 amplification was detected in minority of GC patients, especially in IGC, and was an independent indicator of poor prognosis. Our study, for the first time, found the prognostic value of IKZF3 was superior to HER2 for GC patients.

Indexed as

Gene AmplificationIkaros Transcription FactorStomach NeoplasmsAdultAgedAged, 80 and overBiomarkers, TumorErb-b2 Receptor Tyrosine KinasesFemaleHumansIn Situ Hybridization, FluorescenceIntestinal NeoplasmsMaleMiddle AgedPrognosisBiomarkers, TumorERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesIkaros Transcription FactorIKZF3 protein, humanGastric cancerHER2IKZF3Intestinal-typePrognosis

Identifiers

PMID39052108
PMCPMC11272681

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.